15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 2 of 15

 
 

Novo Nordisk A/S (NYSE:NVO)

Consensus Rating
Moderate Buy
Rating Score
2.8
Ratings Breakdown
6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$133.60 (5.2% Upside)

About Novo Nordisk A/S

Novo Nordisk A/S logoNovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
4/18/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
4/12/2024BMO Capital MarketsInitiated CoverageOutperform$163.00
4/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
3/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
2/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00
2/14/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00
2/1/2024Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$120.00 ➝ $140.00
1/23/2024Morgan StanleyInitiated CoverageOverweight$120.00
1/16/2024UBS GroupInitiated CoverageNeutral
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
 

The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him